Advanced search
Publication Cover
Bioengineered Volume 13, 2022 - Issue 2
Submit an article Journal homepage
813
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Long non-coding RNA BRCAT54 sponges microRNA-21 in vestibular schwannoma to suppress cell proliferation

Gang XiaoNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaCorrespondence[email protected]
View further author information
,
Bin HuangNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
,
Ming GuoNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
,
Chaoxin LongNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
,
Pingan LiNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
,
Bin ZhongNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
&
Chuncheng GuanNeurosurgery Department, North Guangdong People’s Hospital, Shantou University/Medical College, Shaoguan City, PR. ChinaView further author information
 show all
Pages 4301-4308 | Received 21 Nov 2021, Accepted 15 Jan 2022, Published online: 09 Feb 2022

References

  • Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22(1):31–45.
  • Patel NS, Huang AE, Dowling EM, et al. The influence of vestibular schwannoma tumor volume and growth on hearing loss. Otolaryngol Head Neck Surg. 2020;162(4):530–537.
  • Santa Maria PL, Shi Y, Gurgel RK, et al. Long-term hearing outcomes following stereotactic radiosurgery in vestibular schwannoma patients-A retrospective cohort study. Neurosurgery. 2019;85(4):550–559.
  • Nilsen KS, Lund-Johansen M, Nordahl SHG, et al. Long-term effects of conservative management of vestibular schwannoma on dizziness, balance, and caloric function. Otolaryngol Head Neck Surg. 2019;161(5):846–851.
  • Marinelli JP, Lohse CM, Grossardt BR, et al. Rising incidence of sporadic vestibular schwannoma: true biological shift versus simply greater detection. Otol Neurotol. 2020;41(6):813–847.
  • Marinelli JP, Grossardt BR, Lohse CM, et al. Prevalence of sporadic vestibular schwannoma: reconciling temporal bone, radiologic, and population-based studies. Otol Neurotol. 2019;40(3):384–390.
  • Soulier G, van Leeuwen BM, Putter H, et al. Quality of life in 807 patients with vestibular schwannoma: comparing treatment modalities. Otolaryngol Head Neck Surg. 2017;157(1):92–98.
  • Halliday J, Rutherford SA, McCabe MG, et al. An update on the diagnosis and treatment of vestibular schwannoma. Expert Rev Neurother. 2018;18(1):29–39.
  • Long J, Zhang Y, Huang X, et al. A review of drug therapy in vestibular schwannoma. Drug Design, Development and Therapy. 2021;15:75–85.
  • Sylvester MJ, Shastri DN, Patel VM, et al. Outcomes of vestibular schwannoma surgery among the elderly. Otolaryngology–head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2017;156(1):166–172.
  • Shrivastava A, Nair A, Nair S. Vestibular schwannoma: half a decade odyssey from challenges to functional preservation. Neurol India. 2020;68(2):262–263.
  • Fong B, Barkhoudarian G, Pezeshkian P, et al. The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg. 2011;115(5):906–914.
  • Celis-Aguilar E, Lassaletta L, Torres-Martín M, et al. The molecular biology of vestibular schwannomas and its association with hearing loss: a review. Genet Res Int. 2012;2012:856157.
  • Khorkova O, Hsiao J, Wahlestedt C. Basic biology and therapeutic implications of lncRNA. Adv Drug Deliv Rev. 2015;87:15–24.
  • Zhang H, Liu S, Tang L, et al. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9). Bioengineered. 2021;12(1):162–171.
  • Tang D, Geng L, Ma J. lncRNA PROX1-AS1 mediates the migration and invasion of placental trophoblast cells via the miR-211-5p/caspase-9 axis. Bioengineered. 2021;12(1):4100–4110.
  • Yang W, Qian Y, Gao K, et al. LncRNA BRCAT54 inhibits the tumorigenesis of non-small cell lung cancer by binding to RPS9 to transcriptionally regulate JAK-STAT and calcium pathway genes. Carcinogenesis. 2021;42(1):80–92.
  • Cioffi JA, Yue WY, Mendolia-Loffredo S, et al. MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival. Otology & neurotology: official publication of the American Otological Society. American Neurotology Society [and] European Academy of Otology and Neurotology. 2010;31(9):1455–1462.
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods. 2001;25(4):402–408.
  • Grentzmann G, Ingram JA, Kelly PJ, et al. A dual-luciferase reporter system for studying recoding signals. RNA. 1998;4(4):479–486.
  • Cappella P, Gasparri F, Pulici M, et al. Cell proliferation method: click chemistry based on BrdU coupling for multiplex antibody staining. Curr Protoc Cytom. 2015; 722: 7.34. 1-7.34. 17. doi:10.1002/0471142956.cy0734s72.
  • Jalali S, Bhartiya D, Lalwani MK, et al. Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PloS One. 2013;8(2):e53823.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.